Introducing Klogene


The Klotho gene was discovered (published in 1997) by Dr. Makoto Kuro-o; he named it after the goddess Clotho, Zeus’ daughter, who spins the thread of life. Klotho is a large protein produced in the kidney and brain that acts as a circulating growth factor. Klotho-deficient mice show many signs of human aging including cognitive decline, synaptic loss, abnormal CNS myelin, osteoporosis, atherosclerosis and die prematurely. Mice with increased levels of Klotho live 30% longer, are healthier and smarter.

Klogene founder Dr. Carmela Abraham’s team at Boston University School of Medicine was the first to show in 2003 that Klotho levels are lower in the aged brain. Klotho levels are also decreased in the cerebral spinal fluid of Alzheimer’s disease (AD) and multiple sclerosis (MS) patients. In contrast, increased levels of Klotho are associated with improved cognition in humans and mice. In 2005 Dr. Abraham suggested that enhancing Klotho expression has the potential to become a novel therapeutic for age related and other neurodegenerative diseases.

Klogene founders Dr. Assumpcio Bosch and Dr. Miguel Chillon and their team at Universitat Autonoma de Barcelona were the first to show (2015 publication) that expression levels of secreted isoform Klotho (s-KL) are high in the brain, implying that s-KL may have an important role in the central nervous system (CNS). Recently, they published new findings showing that s-KL protects against age-dependent memory deficits, suggesting s-KL’s potential in treatment of cognitive impairment, dementia and Alzheimer’s.

In addition to CNS research on the benefits of Klotho, many academic and industry labs have published papers over the last twenty years on the potential of Klotho as a therapeutic in acute kidney injury and chronic kidney disease (AKI/CKD), certain cancers, diabetes, muscle wasting, atherosclerosis, arteriosclerosis, high blood pressure, stroke, and many other diseases. Klogene’s work is relevant to all of these therapeutic targets.


Klogene is single-gene focused (Klotho), targeting multiple indications, using a variety of approaches to modulate gene expression. The company is headquartered in Boston and uses primarily a virtual company model. In addition to the strong research ties to Boston University School of Medicine and Universitat Autonoma de Barcelona, the company has signed formal collaboration agreements with leading academic and industry research teams in a number of disease areas, as well as general viral vector research and production required for gene therapy. The company’s research and intellectual property include small molecules, zinc finger proteins, RNA targeted compounds, activation with CRISPR dCas9 tools and gene therapy.

The National Institute of Health / National Institute on Aging is funding Klogene research with a $1,490,000 Small Business Innovative Research (SBIR) grant. The company raised seed capital from private investors.

Our Values


We dare to be first in the pursuit of novel therapeutic strategies, striving to improve the lives of those afflicted by debilitating diseases.


We are excited about our research programs and are passionate about the efforts to take them to the clinic.

Sound Practices

We make decisions based on facts, we do what we promise, we execute our plans while being financially conservative.


We show respect to all of our constituents by being ethical, open, honest and fair.